Turmeric
| Summary | |
|---|---|
| Binomial | Curcuma longa L. |
| Family | Zingiberaceae |
| Common names | turmeric (English), haldi (Hindi), haridra (Sanskrit), manjal (Tamil), pasupu (Telugu), jiang huang (Chinese, "yellow ginger"), zard chub (Persian, "yellow wood"), kurkum (Arabic; not to be confused with saffron, which is also kurkum in some Arabic usage), kunyit (Indonesian and Malay); the synonymic binomial Curcuma domestica Valeton appears in some older literature |
| Native range | the Indian subcontinent, where turmeric has been cultivated for at least four thousand years and where India remains the source of approximately 80 percent of world production; cultivated also throughout southeast Asia, southern China, and the tropical Americas |
| Cultivars / varieties | grade-based and color-based; the "fingers" (lateral rhizome branches) are the lower-grade traded product, the "bulbs" (the central rhizome) the higher-grade; Alleppey turmeric from Kerala has the highest curcumin content (5 to 6 percent) and is the preferred grade for therapeutic supplement formulation; Madras turmeric and most Indian commodity turmeric runs 2 to 5 percent curcumin; Curcuma aromatica (yu jin in TCM), Curcuma zedoaria (e zhu in TCM), and Curcuma xanthorrhiza (Javanese turmeric) are distinct species in the same genus with overlapping but distinct uses |
| Parts used | rhizome, the cured-and-dried form (the fresh rhizome is also used in Indian and southeast Asian cooking and traditional medicine); the leaves are used in some Indian cuisine but not medicinally |
| Cultivation | tropical herbaceous perennial; tuberous rhizome propagated vegetatively; nine to ten month growing season; rhizomes harvested at leaf senescence, boiled or steamed briefly to gelatinize the starch and inactivate the sprouting enzymes, then sun-dried and polished; the cured rhizome is what enters trade as "turmeric" |
| Pharmacy | |
| Preparations | rhizome powder 1 to 4 g daily (culinary and traditional therapeutic dose); standardized curcuminoid extract 500 to 2000 mg daily (95 percent curcuminoid content typical); curcumin with piperine (Curcuma longa + Piper nigrum, the bioavailability-enhanced classical combination) at 500 to 2000 mg curcumin plus 5 to 20 mg piperine; phytosome formulations (Meriva, Theracurmin, BCM-95, others) at the manufacturer-specified dose, which deliver substantially higher systemic curcumin than plain powder; tincture 1:5 in 45 percent alcohol, 2 to 4 mL three times daily; the traditional topical Lepa (paste of turmeric, sandalwood, neem, and other powders) for skin complaint; the traditional infusion in milk (haridra dugdha, "golden milk") for respiratory and warming use |
| Pregnancy | culinary doses safe; therapeutic-dose supplementation, particularly high-bioavailability formulations, caution; traditional sources name turmeric as an emmenagogue and uterine tonic at medicinal dose |
| Legal status | unscheduled; GRAS for culinary use; widely sold worldwide as culinary spice, traditional remedy, and dietary supplement |
| Pharmacology | |
| Active constituents | curcuminoids 2 to 8 percent of dried rhizome by weight (curcumin approximately 70 percent of the curcuminoid fraction, demethoxycurcumin approximately 20 percent, bisdemethoxycurcumin approximately 10 percent); essential oil 3 to 5 percent (turmerones the principal volatile component: ar-turmerone, alpha-turmerone, beta-turmerone, with smaller amounts of zingiberene and curlone); starch 60 to 70 percent of dried rhizome (the bulk of the dry weight); polysaccharides; minor terpenoids and flavonoids |
| Mechanism (summary) | curcumin inhibition of nuclear factor kappa B (NF-kB) transcription, cyclooxygenase-2 (COX-2), and lipoxygenase (LOX), with downstream reduction of pro-inflammatory cytokines (TNF-alpha, IL-1, IL-6) is the principal mechanistic rationale for the anti-inflammatory effects; curcumin direct radical scavenging and glutathione-system upregulation account for the antioxidant activity; turmerones have separate pharmacological activity (immunomodulatory and aromatic carminative); the bioavailability problem (free curcumin oral absorption is approximately 1 percent and what is absorbed is rapidly glucuronidated and sulfated by UGT and SULT enzymes) constrains the in vivo effect substantially relative to in vitro and animal-model findings, and accounts for the limited clinical-trial effect sizes despite extensive preclinical evidence |
Turmeric is the dried, cured rhizome of Curcuma longa L., a tropical herbaceous perennial of the Zingiberaceae (the ginger family) native to the Indian subcontinent and cultivated continuously there for at least four thousand years as the principal food coloring, ritual aromatic, and anti-inflammatory medicine of the South Asian tradition. The Sanskrit name haridra (literally "yellow," from the same root as the Persian zard chub, "yellow wood") names the rhizome for the yellow color that has anchored its dual sacred-and-medicinal identity in Hindu, Buddhist, and Jain practice: turmeric paste is applied to the bride and groom in the Indian wedding haldi ceremony, used as a ritual offering in temple worship, smeared on the forehead as a daily mark of auspicious blessing, and ground into the medicinal pastes (Lepa) of classical Ayurvedic external practice for thousands of years. The rhizome is documented in the Charaka Samhita and Sushruta Samhita (the foundational Ayurvedic texts compiled in the early centuries of the common era from older oral tradition) as a warming, drying, bitter, and pungent medicine indicated for indigestion, wound healing, skin disorders, blood-purification, diabetes, respiratory complaint, and inflammatory pain;[1] the bandwidth of classical indications is unusually broad even by Ayurvedic standards and matches the breadth of curcumin's in vitro pharmacology. Turmeric entered the Chinese materia medica as jiang huang ("yellow ginger") by the Tang dynasty, where it is classed as a blood-mover and qi-mover for amenorrhea, abdominal masses, and traumatic injury;[2] the Persian and Islamic traditions received it as zard chub and kurkum but treated it as a secondary aromatic and dyestuff rather than as a central medicinal herb. The modern Western use of turmeric dates almost entirely from the late twentieth century, when the in vitro pharmacology of curcumin (the principal yellow pigment of the rhizome) attracted research attention in anti-inflammatory, antioxidant, and anticancer pharmacology, and turmeric and its standardized curcumin extracts became one of the most widely sold dietary supplements in the United States and Europe.
History and traditional use
The Indian subcontinent is the historical centroid of turmeric, and the depth of Indian use is unusual even by the standards of widely-traded medicinal spices. Archaeological evidence from Indus Valley sites suggests turmeric was in cultivation in the Indian subcontinent by approximately 2500 BCE,[3] and the rhizome appears in the post-Vedic literary record as haridra (the Sanskrit name) from at least the first millennium BCE. The classical Ayurvedic texts the Charaka Samhita and Sushruta Samhita document turmeric extensively: Charaka classes haridra as warming (ushna virya), drying (ruksha), bitter-and-pungent (tikta-katu rasa), kapha-vata-shamaka (pacifying the cold-and-damp and the cold-and-windy doshas), and indicates it for indigestion (agnimandya), wound healing (vrana ropana), skin disorders broadly (kushta), blood-purification (raktashodhana), diabetes mellitus (madhumeha), respiratory complaint, and inflammatory joint pain.[4] Sushruta's surgical text emphasizes the topical wound application of turmeric powder for its antiseptic and granulation-promoting effect, a use that has persisted in Indian folk and clinical practice to the present and that has substantial supporting in vitro evidence for cinnamaldehyde-equivalent antimicrobial activity. Classical Ayurvedic compound formulations including turmeric are numerous: Haridra Khanda (turmeric in a herbal-mineral compound for skin disorders), Mahasudarshana Churna (turmeric among many ingredients, for fever and detoxification), Yashtimadhukadi Ghrita, and many others.
The Indian sub-tradition of turmeric in milk (haridra dugdha, or in the modern Anglophone packaging "golden milk") deserves separate notice. The traditional formulation combines warm milk with turmeric, black pepper, ginger, cardamom, and (sometimes) saffron, often sweetened with jaggery or honey; the indication is for respiratory complaint, cough, sore throat, joint pain, and general warming-and-restoration in convalescence. The formulation is culturally salient, widely used in modern Indian and diaspora households, and has been the basis of a substantial Western supplement and beverage industry over the past two decades. Pharmacokinetically, however, the systemic curcumin delivery from a cup of turmeric milk is essentially nil (the curcumin content of a teaspoon of turmeric powder is at most 200 mg, and the oral bioavailability without piperine co-administration is approximately 1 percent, yielding less than 2 mg of bioavailable curcumin); the traditional clinical effect rests on the warming-aromatic-pungent profile of the formulation and on the demulcent and protein content of the milk rather than on systemic curcumin pharmacology. This is a useful distinction for prescribers: the cultural-traditional use of turmeric in milk is real, broadly safe, and culturally significant, but it should not be confused with the bioavailability-engineered supplement use of standardized curcuminoid extract.
The Chinese tradition received turmeric as jiang huang ("yellow ginger") via Indian trade by the Tang dynasty (618 to 907 CE), where it was incorporated into the materia medica as a blood-mover (huo xue), qi-mover (xing qi), and pain reliever; the principal TCM indications are amenorrhea, dysmenorrhea with palpable abdominal masses, post-traumatic pain, and rheumatic joint pain.[5] The TCM tradition recognizes three distinct Curcuma "yellow" herbs from different species in the genus: jiang huang from C. longa (the bark-yellow rhizome, the warming blood-and-qi-mover); yu jin from C. aromatica or C. wenyujin (the heart-yellow rhizome, cooling, used for liver-qi stagnation with heat); and e zhu from C. zedoaria (the white-blue rhizome, the strongest blood-mover, used for abdominal masses). The three are distinct in clinical use within TCM despite arising from sibling species and being often confused outside the tradition.
The Islamic and Persian medical traditions received turmeric as zard chub (Persian, "yellow wood") and kurkum (Arabic, also a name shared with saffron in some Arabic usage and a recurrent source of confusion in classical pharmacological texts). Avicenna's Canon mentioned zard chub among the warming, drying, and pungent simples for digestive complaint and topical wound application, but turmeric never reached the central pharmacopoeial role in the Unani tradition that ginger or cinnamon held; turmeric in Unani practice was largely a dyestuff and secondary aromatic, with the medicinal centroid of the herb remaining firmly in South Asia.
The European reception of turmeric was minor through the early modern period. Turmeric followed the broader curry-spice trade from India to European markets but was treated chiefly as a dyestuff and culinary coloring rather than as a medicinal herb in the European pharmacopoeial tradition; the formal Western pharmacopoeial monographs of the eighteenth and nineteenth centuries acknowledged turmeric as a tinctorial commodity and only marginally as a digestive aromatic. This relative European indifference persisted until the late twentieth century, when in vitro pharmacological investigation of curcumin attracted research attention to the rhizome and turmeric began its modern transition from spice to clinical supplement.
The modern bioavailability story is the defining pharmacokinetic narrative of curcumin and is essential to interpreting the clinical-trial literature on the herb. Free oral curcumin is absorbed at approximately 1 percent of the administered dose, and what is absorbed is rapidly glucuronidated and sulfated by intestinal and hepatic UGT and SULT enzymes, so that free curcumin in plasma is essentially undetectable at typical supplement doses. The Shoba 1998 study documented that co-administration of piperine (from Piper nigrum, black pepper) inhibited the conjugation enzymes and increased curcumin systemic bioavailability approximately twentyfold in human volunteers,[6] a finding that codified the traditional Indian culinary pairing of turmeric and black pepper into a pharmacokinetic rationale and that has been the basis of most modern curcumin supplement formulations. A second generation of bioavailability-enhanced formulations (Meriva, the curcumin phospholipid phytosome complex; Theracurmin, the colloidal nanoparticle dispersion; BCM-95, the curcumin-with-essential-oils complex) increase oral bioavailability further by various carrier-system mechanisms and now constitute the majority of curcumin supplements sold in the Western market. The clinical implication is that the trial-literature effect sizes for turmeric and curcumin in inflammatory disease depend substantially on the formulation studied, and that translation from positive trial results in bioavailability-engineered formulations to the everyday consumer use of plain turmeric powder is not straightforward.
The contemporary controlled-trial literature on turmeric and curcumin for inflammatory disease is substantial and heterogeneous. The most-studied indication is osteoarthritis: head-to-head trials of curcuminoid extracts against ibuprofen and other anti-inflammatory medicines have generally found non-inferiority for symptomatic relief over short courses,[7] and several systematic reviews and meta-analyses have reported modest but statistically significant improvement in osteoarthritis pain scores with curcuminoid supplementation, with substantial heterogeneity attributable to formulation differences.[8] Ulcerative colitis maintenance with curcumin in addition to standard mesalamine therapy has been investigated in small trials with modest positive results.[9] Depression adjunct trials of curcumin have produced mixed findings, with some short trials reporting non-inferiority to fluoxetine and other reports finding no significant effect.[10] Where the observational and short-trial evidence has supported indications for inflammatory and neurological disease, larger and longer randomized trials have produced more modest effect sizes, and the curcumin research field has additionally been affected by retractions of multiple prominent papers from a single academic laboratory, contributing to a more cautious modern assessment of curcumin's clinical evidence base than was current a decade ago.[11] The interpretation for a prescriber is that curcumin's anti-inflammatory effect at clinically meaningful intake is real but modest, that bioavailability-engineered formulations are typically required to deliver clinically interesting plasma concentrations, and that any single trial should be read in the context of formulation and of the field's evolving credibility profile.
A growing case-report literature documents hepatotoxicity associated with chronic high-dose curcumin supplementation, particularly with high-bioavailability formulations and particularly in chronic supplementation extending beyond a few months. Case reports have accumulated since approximately 2018, with several published in 2020 to 2023 documenting acute hepatitis presentation in patients on multi-month high-dose curcumin or Meriva-type phytosome supplementation, generally with resolution on discontinuation.[12] The NIH LiverTox database lists turmeric and curcumin as known hepatotoxicants at supplementation dose, with the bioavailability-enhanced formulations identified as the higher-risk preparations.[13] The signal is real but rare in absolute terms relative to the magnitude of turmeric and curcumin supplementation worldwide; the clinical implication is that prescribers should counsel patients on chronic high-dose curcumin supplementation about the hepatotoxicity risk, monitor liver function in chronic users, and consider the dose-and-formulation choice (whether to use bioavailability-enhanced formulations or to accept lower bioavailability from plain turmeric powder) as a benefit-risk decision rather than a default. Culinary use of turmeric at the gram-per-day scale typical of Indian and southeast Asian cooking is essentially without hepatotoxicity risk.
Botany and identification
Curcuma longa is a tropical herbaceous perennial of the Zingiberaceae reaching 60 to 90 cm at flowering. The plant emerges annually from a tuberous rhizome, sending up large oblong leaves 30 to 50 cm long and 7 to 15 cm wide, glossy green with a prominent central midrib, arranged in a tight basal rosette. The inflorescence is a dense terminal spike of pale yellow flowers subtended by green and rosy-pink bracts (the bracts the more conspicuous floral feature). The medicinally used rhizome is the central tuberous body and its lateral branches: the central rhizome ("bulb") is rounded, 3 to 6 cm in diameter, with the lateral branches ("fingers") elongated and 1 to 2 cm in diameter, both intensely yellow-orange when cut, with a distinctive warm aromatic odor and pungent-bitter taste. Distinguished from the related Curcuma aromatica (Indian wild turmeric, the TCM yu jin) by smaller rhizome and more pungent aroma; from Curcuma zedoaria (white turmeric, the TCM e zhu) by deeper yellow rhizome color and less camphorous aroma; from Zingiber officinale (ginger, the most likely confusion in fresh-rhizome form) by deeper yellow color throughout and absence of ginger's distinctive zingerone-and-gingerol pungency. The dried-cured rhizome of commerce is hard, dense, intensely yellow, breaks with a clean crystalline fracture, and powders to the characteristic mustard-yellow color that has anchored turmeric's dual culinary-and-dye identity.
Active constituents
The principal medicinally active constituents of turmeric are the curcuminoids (polyphenolic pigments of the diarylheptanoid class) and the essential oil (rich in sesquiterpene ketones called turmerones).
The curcuminoid fraction is 2 to 8 percent of dried rhizome by weight, varying by cultivar, region, and curing practice. The fraction comprises three principal compounds: curcumin (approximately 70 percent of the curcuminoid fraction, the principal pigment and the focus of essentially all modern curcumin research), demethoxycurcumin (approximately 20 percent, somewhat more bioavailable than curcumin), and bisdemethoxycurcumin (approximately 10 percent, the most stable to oxidation). Curcumin is the diferuloylmethane molecule, with two ferulic acid units bridged by a heptadienedione linker; the molecule exists in equilibrium between keto and enol tautomers and is the principal bright-yellow pigment of the rhizome. Curcumin is poorly water-soluble, sensitive to alkaline pH and light, and undergoes rapid degradation in physiological aqueous solution to ferulic acid, vanillin, and related smaller molecules; some of curcumin's observed in vitro pharmacology may be attributable to these degradation products rather than to curcumin itself.
The essential oil fraction is 3 to 5 percent of dried rhizome by weight and is dominated by turmerones: ar-turmerone (the aromatic turmerone, the principal volatile component, with characteristic warm-spicy aroma), alpha-turmerone, and beta-turmerone, together with smaller amounts of zingiberene (shared with ginger), curlone, and other sesquiterpenes. The turmerones have substantially better oral bioavailability than curcumin and contribute independently to turmeric's pharmacology; the immunomodulatory and aromatic carminative effects of turmeric appear to depend more on the turmerones than on curcumin in vivo, although the modern supplement industry has focused almost entirely on curcuminoid standardization.
The non-active fractions are dominated by starch (60 to 70 percent of dried rhizome dry weight, the bulk of the rhizome carbohydrate), polysaccharides, and small amounts of protein, mineral, and minor terpenoid and flavonoid compounds.
Preparations
The traditional Indian and southeast Asian forms are the cured rhizome powder (the form of commerce, 1 to 4 g daily for culinary and traditional therapeutic use); the fresh rhizome (used in Indian and Thai cooking and in some traditional folk preparations); the topical Lepa (paste of turmeric powder with sandalwood, neem, and other powders, mixed with water or rosewater to a paste, applied externally for skin complaint); the haridra dugdha or "golden milk" (turmeric powder simmered in milk with black pepper, ginger, and sometimes cardamom and jaggery, used as a warming beverage for respiratory and inflammatory complaint).
The modern Western forms are the standardized curcuminoid extract (95 percent curcuminoid content, typically supplied as 500 mg or 1000 mg capsules, with daily doses of 500 to 2000 mg curcuminoid); the curcumin-piperine combination (curcumin extract with 5 to 20 mg added piperine from Piper nigrum, the bioavailability-enhanced classical pairing); and the bioavailability-enhanced proprietary formulations including Meriva (curcumin phospholipid phytosome complex, ~30-fold bioavailability enhancement), Theracurmin (colloidal nanoparticle dispersion, ~27-fold enhancement), BCM-95 (curcumin with turmeric essential oils, ~7-fold enhancement), and others. The proprietary formulations are the basis of most positive curcumin clinical trial results in the past decade. The tincture (1:5 in 45 percent alcohol, 2 to 4 mL three times daily) is the traditional Western herbalist's form but delivers low systemic curcumin.
Pharmacokinetics
Curcumin absorbed from the gastrointestinal tract at approximately 1 percent of administered oral dose; what is absorbed is rapidly conjugated by UGT (UDP-glucuronosyltransferase, especially UGT1A1) and SULT (sulfotransferase) enzymes in intestinal mucosa and liver to curcumin glucuronide and curcumin sulfate, which are the principal circulating forms; free unconjugated curcumin is essentially undetectable in plasma at typical supplemental doses without bioavailability enhancement. Curcumin glucuronide undergoes biliary excretion and enterohepatic recycling; ultimate elimination is largely fecal, with a smaller urinary fraction. Co-administration of piperine inhibits both UGT (by direct enzyme interaction and by altering membrane fluidity) and CYP3A4, producing the approximately 2000 percent increase in curcumin bioavailability documented in the Shoba 1998 trial; the practical effect is that piperine-co-administered curcumin reaches plasma concentrations in the nanomolar-to-low-micromolar range from typical supplemental doses, sufficient to engage the proposed pharmacological targets at least transiently. Phytosome (Meriva, Theracurmin) and similar carrier-system formulations achieve comparable or higher bioavailability by different mechanisms (lipid-phase partitioning bypassing some first-pass conjugation, colloidal nanoparticle absorption). The pharmacokinetic profile of the curcumin metabolites (glucuronide, sulfate) is itself pharmacologically relevant: some in vivo curcumin pharmacology may be attributable to the conjugated metabolites or to enterohepatically recycled material rather than to free curcumin in systemic circulation.
The turmerones have separate, substantially better oral pharmacokinetic profiles than curcumin, with absorption in the 10 to 30 percent range and lower first-pass conjugation; the turmerones contribute independently to turmeric's systemic pharmacology in a way that the curcumin-focused supplement industry has generally underweighted.
Pharmacodynamics
Curcumin in vitro is a broad-spectrum inhibitor of inflammatory signaling: nuclear factor kappa B (NF-kB) transcription, cyclooxygenase-2 (COX-2), 5-lipoxygenase (5-LOX), and several pro-inflammatory cytokines (TNF-alpha, IL-1 beta, IL-6) are downregulated by curcumin at micromolar concentrations. Curcumin also directly scavenges reactive oxygen species and upregulates glutathione system enzymes (gamma-glutamylcysteine synthetase, glutathione peroxidase, glutathione reductase), accounting for its substantial in vitro antioxidant capacity. Curcumin inhibits platelet aggregation in vitro through reduction of thromboxane A2 synthesis and direct platelet membrane effects; this is the mechanistic rationale for the additive antiplatelet interaction with anticoagulants and antiplatelet medicines. Curcumin has documented in vitro effects on tumor cell apoptosis, angiogenesis inhibition, and cell-cycle modulation that have been the basis of extensive (and substantially retracted) preclinical anticancer literature; the translation of these in vitro effects to clinically meaningful in vivo anticancer activity has not been established.
The turmerones produce immunomodulatory effects in animal models (macrophage activation, lymphocyte response modulation) that are distinct from curcumin's NF-kB inhibition; the aromatic-carminative effect of turmeric on digestive function is mediated primarily by the turmerones rather than by curcumin, and accounts for the Commission-E-approved dyspepsia indication that does not depend on systemic curcumin pharmacology.
The bioavailability constraint is the bridge between the rich in vitro pharmacology of curcumin and the modest in vivo clinical effect: in vitro effective concentrations of curcumin in the low micromolar range are difficult to achieve in plasma even with bioavailability-engineered formulations, and the systemic effects of turmeric supplementation in vivo may depend as much on the turmerone fraction and on conjugated curcumin metabolites as on free systemic curcumin.
Experience
Log in to add your own experience.
Problems
Anti-inflammatory adjunct for osteoarthritis (the most-studied modern indication; modest effect; comparable to non-steroidal anti-inflammatory medicines in short-course head-to-head trials of bioavailability-enhanced formulations). Ulcerative colitis maintenance therapy in combination with standard mesalamine treatment (modest evidence base from small trials). Functional dyspepsia and indigestion (Commission E approved for this indication; the traditional digestive carminative use). Wound healing, topical (the classical Ayurvedic and folk application; modest in vitro and case-series evidence). Adjunctive for major depression (mixed trial evidence; not a primary intervention). Cardiovascular and metabolic indications (mixed observational and trial evidence, generally modest). Traditional Ayurvedic indications: skin disorders (kushta), blood-purification (raktashodhana), diabetes mellitus (madhumeha), respiratory complaint, joint pain. Traditional TCM indications: amenorrhea, dysmenorrhea with abdominal mass, post-traumatic pain, rheumatic joint pain (jiang huang). Folk indication: the warming-respiratory use in turmeric milk for cough and convalescence.
Titration and dosing
Rhizome powder: 1 to 4 g daily, divided. Standardized curcuminoid extract (95 percent curcuminoids): 500 to 2000 mg daily, divided. Curcumin with piperine: 500 to 2000 mg curcumin plus 5 to 20 mg piperine daily, divided. Bioavailability-enhanced proprietary formulations: per manufacturer specification (typical Meriva dose 1000 to 2000 mg of the phytosome complex daily, which delivers approximately 200 to 400 mg bioavailable curcumin equivalent). Tincture 1:5 in 45 percent alcohol: 2 to 4 mL three times daily. Topical Lepa: applied to the lesion in paste form, allowed to dry, removed after 30 to 60 minutes. Turmeric milk: 1 teaspoon (approximately 2 g) turmeric powder per cup of warm milk, traditionally taken once or twice daily for cough or warming use. TCM jiang huang in decoction: 3 to 10 g daily in compound formula.
Effects
No effects listed yet, be the first to suggest one.
Interactions
The clinically significant interactions of turmeric and curcumin are modest in number but include one substantive concern.
Antiplatelet and anticoagulant interaction. Curcumin inhibits platelet aggregation in vitro, and case reports document increased bleeding risk and elevated INR in patients on warfarin who add high-dose curcumin supplementation; the effect is theoretical at culinary doses, somewhat more substantial at supplementation doses, and most pronounced with bioavailability-enhanced formulations. The conservative recommendation is to avoid therapeutic-dose curcumin supplementation in patients on warfarin or DOACs without prescriber consultation, and to discontinue therapeutic-dose curcumin supplementation seven to ten days before elective surgery (parallel to the garlic and ginkgo recommendation for the same antiplatelet category). Culinary turmeric does not require preoperative discontinuation.
CYP3A4 modest inhibition, particularly with piperine-enhanced curcumin or phytosome formulations, has been documented in pharmacokinetic studies; the clinical magnitude is generally modest but can be relevant for medicines with narrow therapeutic windows and known CYP3A4 substrate dependence (cyclosporine, tacrolimus, some antiretrovirals, several oncology agents). Patients on such medicines who add high-dose curcumin supplementation should monitor for the relevant pharmacokinetic interaction.
Hepatotoxicity at chronic high-bioavailability supplementation. This is the principal modern safety concern for turmeric and is distinct from any pharmacological interaction with another medicine: the risk is intrinsic to chronic high-dose curcumin exposure, particularly with bioavailability-enhanced formulations that achieve substantially higher plasma concentrations than plain turmeric powder. The signal is real, the case-report literature is growing, and the mechanistic understanding (oxidative stress, mitochondrial dysfunction, possible idiosyncratic immune component) is incomplete. The conservative recommendation for chronic supplementation users is liver function monitoring at baseline and periodically; discontinuation at any sign of hepatic dysfunction; and a low threshold to substitute plain turmeric for bioavailability-enhanced formulations or to discontinue supplementation entirely if the indication is itself marginal.
Pregnancy and lactation
Culinary amounts of turmeric are considered safe in pregnancy and lactation with a long historical record in essentially all turmeric-using cultures, particularly the Indian subcontinent where daily culinary intake is the norm. The traditional Ayurvedic and folk caution about turmeric in pregnancy applies to medicinal-dose use, not to culinary use: classical sources name turmeric as warming and as a mild emmenagogue at therapeutic dose, with the late-pregnancy concern being premature uterine activity. Therapeutic-dose supplementation, particularly high-bioavailability formulations and curcumin extracts, has not been formally studied in pregnancy and is best avoided; the hepatotoxicity risk and the theoretical antiplatelet effect both compound the conservative recommendation against therapeutic-dose supplementation in pregnancy.
Monitoring
For patients on warfarin or DOACs who consume turmeric at any consistent therapeutic-dose level, INR monitoring at the initiation of regular consumption and again at three to four weeks is the conservative practice; therapeutic-dose supplementation is best avoided rather than monitored in patients on warfarin. For chronic high-dose curcumin supplementation (above 1 g daily of standardized curcuminoid extract or any chronic bioavailability-enhanced formulation), liver function testing at baseline and periodically (every six to twelve months) is the conservative practice in patients with pre-existing hepatic disease or concurrent hepatotoxic medicine use; the signal of supplement-associated hepatotoxicity is substantial enough to warrant monitoring at this level of exposure regardless of additional risk factors in patients on indefinite supplementation regimens.
Patient counseling
Patients should be counseled that culinary turmeric (gram-per-day scale, as used in Indian, southeast Asian, and Caribbean cooking and in turmeric-milk preparations) is broadly safe, has the long historical record of Indian sub-continental use to support its safety profile, and delivers modest amounts of pharmacologically active compound through the turmerone fraction and through small amounts of cumulative curcumin metabolites. The traditional pairing of turmeric with black pepper in Indian cuisine is the culinary precedent for the modern piperine-curcumin supplement formulations and substantially enhances curcumin bioavailability.
The shift from culinary turmeric to therapeutic-dose curcumin supplementation is a meaningful change in pharmacology and risk profile. Standardized curcuminoid extracts deliver substantially more curcumin per dose than culinary use, and bioavailability-enhanced formulations (Meriva, Theracurmin, and similar) deliver substantially higher systemic curcumin concentrations than plain extracts. The clinical effect on inflammatory disease is modest at best at any of these dose levels; the hepatotoxicity risk increases with dose and bioavailability enhancement and is the principal modern safety concern for the herb.
For patients who choose curcumin supplementation for inflammatory indication: a reasonable approach is to begin with the lower end of the dose range (500 mg of standardized curcuminoid extract daily, with or without piperine), to assess clinical effect over four to eight weeks, and to discontinue if no benefit is apparent. Indefinite multi-year high-dose supplementation, particularly with bioavailability-enhanced formulations, carries the hepatotoxicity concern and warrants periodic LFT monitoring. Patients should be counseled to discontinue any curcumin supplementation immediately if they develop jaundice, dark urine, unexplained nausea, or right-upper-quadrant abdominal discomfort, and to consult their prescriber.
Turmeric powder applied topically can stain skin and clothing yellow; the cosmetic staining resolves over days to a week on skin and is generally permanent on light-colored fabric. Patients using topical turmeric paste for skin complaint should be counseled to apply at times when temporary yellow staining is acceptable and to test for cinnamaldehyde-equivalent contact dermatitis on a small area before broader application.
The traditional pregnancy caution against medicinal turmeric (as distinct from culinary use) reflects a real if modest emmenagogue effect at high dose; pregnant patients should be counseled to limit themselves to culinary doses and to avoid curcumin extract supplementation entirely in pregnancy.
Relevant anecdote
No anecdotes yet, share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
See also
Ginger, Cardamom, Black pepper, Cinnamon, Ceylon cinnamon, Cassia cinnamon, Cloves, Boswellia, Garlic
References
- ↑ Sharma PV (translator). Charaka Samhita: Text with English Translation. Varanasi: Chaukhambha Orientalia; 1981.
- ↑ Bensky D, Clavey S, Stoger E. Chinese Herbal Medicine: Materia Medica, 3rd ed. Seattle: Eastland Press; 2004.
- ↑ Kashyap A, Weber SA. Harappan plant use revealed by starch grains from Farmana, India. Antiquity 2010;84(326), Project Gallery. Archaeobotanical starch-grain analysis identifying turmeric, ginger, and other Zingiberaceae in Harappan-period cooking residues.
- ↑ Williamson EM. Major Herbs of Ayurveda. Edinburgh: Churchill Livingstone; 2002.
- ↑ Bensky D, Clavey S, Stoger E. Chinese Herbal Medicine: Materia Medica, 3rd ed. Seattle: Eastland Press; 2004.
- ↑ Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica. 1998 May;64(4):353-356. PMID 9619120.
- ↑ Kuptniratsaikul V, Dajpratham P, Taechaarpornkul W, Buntragulpoontawee M, Lukkanapichonchut P, Chootip C, et al. Efficacy and safety of Curcuma domestica extracts compared with ibuprofen in patients with knee osteoarthritis: a multicenter study. Clinical Interventions in Aging. 2014;9:451-458. PMID 24672232.
- ↑ Daily JW, Yang M, Park S. Efficacy of turmeric extracts and curcumin for alleviating the symptoms of joint arthritis: a systematic review and meta-analysis of randomized clinical trials. Journal of Medicinal Food. 2016 Aug;19(8):717-729. PMID 27533649.
- ↑ Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clinical Gastroenterology and Hepatology. 2006 Dec;4(12):1502-1506. PMID 17101300.
- ↑ Sanmukhani J, Satodia V, Trivedi J, Patel T, Tiwari D, Panchal B, et al. Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. Phytotherapy Research. 2014 Apr;28(4):579-585. PMID 23832433.
- ↑ Retraction Watch. Database of retracted papers in curcumin / turmeric pharmacology research; ongoing coverage since 2014. Available at https://retractionwatch.com/ (search "curcumin" or "Aggarwal" for the relevant cluster of retractions in the modern curcumin literature).
- ↑ Lukefahr AL, McEvoy S, Alfafara C, Funk JL. Drug-induced autoimmune hepatitis associated with turmeric dietary supplement use. BMJ Case Reports. 2018 Sep 10;2018:bcr-2018-224611. PMID 30206065.
- ↑ National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, Turmeric and Curcumin entry. Bethesda, MD: NIDDK; ongoing updates. Available at https://www.ncbi.nlm.nih.gov/books/NBK548561/